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Background: Epidermal growth factor receptor (EGFR) gene copy
number has been proposed as predictor of response to epidermal
growth factor receptor tyrosine kinase inhibitors in advanced non-
small cell lung cancer (NSCLC).
Methods: Cytologic and matched histologic samples from 33 pri-
mary non-small cell lung cancers were analyzed by fluorescence in
situ hybridization (FISH) for epidermal growth factor receptor gene.
Results: FISH was positive in 52% and negative in 35% of the 31
matched evaluable samples. Four of 31 (13%) cases were discordant
(K  0.736; p  0.001).
Conclusion: Our data support the feasibility and reliability of epider-
mal growth factor receptor gene assessment by FISH on cytology.
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Epidermal growth factor receptor (EGFR) is frequentlyoverexpressed in non-small cell lung cancer (NSCLC) and
its activation is involved in tumor development and progres-
sion.1 Gefitinib and erlotinib, small molecules reversibly
binding the adenosine triphosphate pocket in the EGFR
intracellular tyrosine kinase domain, represent a new option
in the treatment of NSCLC.2 Nevertheless, it seems that a
higher benefit can be obtained with EGFR tyrosine kinase
inhibitors (TKIs) in patients with some clinical characteris-
tics, such as female gender, never smoking status, Asian
ethnic origin, and adenocarcinoma histotype.3
Although clinical characteristics may identify candidates
for EGFR TKIs, the ideal patient selection should mostly rely on
biologic tumor features.4 In particular, in 2005, Cappuzzo et al.5
reported for the first time the observation that EGFR gene copy
number as detected by fluorescence in situ hybridization (FISH)
on tumor samples may predict EGFR TKI treatment outcome in
patients with advanced NSCLC. Further studies confirmed this
observation leading to an increased use of EGFR FISH in
clinical practice.6,7 One significant limitation, however, is that
FISH analysis requires adequate histologic sampling. Unfortu-
nately, at diagnosis, many NSCLCs present at an advanced stage
when surgery is not recommended and a considerable fraction of
them is diagnosed by cytology only. For this reason and because
almost all of the published data on EGFR gene copy number
analyses were made on histologic material, it is relevant to assess
feasibility and reliability of EGFR FISH on cytologic specimens.
The aim of this study was to compare EGFR FISH results
assessed on cytologic samples from primary NSCLC with those
obtained on matched histologic sections.
PATIENTS AND METHODS
The current series included cytologic and histologic
specimens from 33 primary NSCLCs. Fourteen were adeno-
carcinomas, 14 squamous cell carcinomas, 3 adenosquamous
carcinomas, 1 sarcomatoid carcinoma, and 1 NSCLC not
otherwise specified. Twenty-two of the 33 cytologic samples
were smears obtained by transthoracic needle aspiration and
by transbronchial needle aspiration in 16 and 6 cases, respec-
tively, whereas 11 were imprints from tumor-positive bron-
chial biopsies. Histologic samples were obtained from 16
bronchial biopsies and 17 surgical specimens.
Cytologic preparations were submitted to May-Grun-
wald Giemsa staining for routine cytologic diagnosis, as well
as to EGFR evaluation by FISH. Cytologic samples for
EGFR FISH were kept unstained at 20°C until assay.
Moreover, 4--thick histologic sections of the matched pri-
mary tumors, obtained simultaneously to cytology during
bronchoscopy or subsequently by surgery, were evaluated by
FISH. FISH assays were performed using the LSI EGFR
SpectrumOrange/CEP7 SpectrumGreen dual-color probe set
(Vysis, Downers Grove, IL) as previously described8 and
assessed by two independent blinded observers (C.B., C.L.).
At least 100 cells per case were scored for both EGFR and
chromosome 7 signals for both cytology and histology. Ac-
cording to Colorado scoring system,5 patients were classified
into six FISH strata with ascending number of copies of the
EGFR gene per cell according to the frequency of tumor cells
with specific number of copies of the EGFR gene and
chromosome 7 centromere: (1) disomy (2 copies in 90%
of cells); (2) low trisomy (2 copies in 40% of cells, 3
copies in 10–40% of the cells, 4 copies in 10% of cells);
(3) high trisomy (2 copies in 40% of cells, 3 copies in
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40% of cells, 4 copies in 10% of cells); (4) low
polysomy (4 copies in 10–40% of cells); (5) high poly-
somy (4 copies in 40% of cells); and (6) gene amplifi-
cation (defined by presence of tight EGFR gene clusters and
a ratio of EGFR gene to chromosome of2 or15 copies of
EGFR per cell in10% of analyzed cells). Patients with high
gene copy numbers (gene amplification or high polysomy)
were designated FISH positive and patients in all other
categories (disomy, low trisomy, high trisomy, and low
polysomy) were categorized as FISH negative.
Concordance between EGFR FISH status on cytologic
versus histologic samples was indicated by the ratio on
concordant cases to total cases. Kappa coefficient was used to
assess the level of agreement between the two methods.
Kappa values ranging from 0.61 to 0.8 were assumed to
indicate a very good agreement; p 0.05 allowed us to reject
the null hypothesis that there is no agreement.
RESULTS
EGFR FISH was feasible in 94% (31 of 33) of both
cytology and histology samples. Failure of FISH cytology
was due to unsuccessful hybridization on a destained May-
Grunwald Giemsa smear in one case and due to the insuffi-
cient number of tumor cells present on the slide in another
case. EGFR FISH was positive according to Colorado scoring
system5 criteria in 19 of 31 (61%) cytologic and in 17 of 31
(55%) histologic matched samples (Table 1). Sixteen of 31
cases (52%) were FISH positive and 11 (35%) were negative
at both cytology and matched histology (concordance: 27 of
31, 87%) (Table 2). Among FISH-positive tumors, two were
amplified at both cytology and histology. Figure 1 shows
three different EGFR assets on cytologic smears. Only 4 of
31 (13%) proved discordant at cytology versus histology
(K  0.736; p  0.001), one case being FISH positive at
histology but not at cytology and vice versa in the remaining
three. Of these three latter cases, two displayed a heteroge-
neous EGFR FISH pattern at histology, with a highly poly-
somic component in 40% of analyzed cells.
Eight of the 31 histologic samples were considered
heterogeneous, because they showed a different EGFR asset
in different areas of the same tumor. This heterogeneity was
present also in 5 of the matched cytologic samples; 2 of the
8 (25%) heterogeneous cases showed histology versus cytol-
ogy FISH discordance. Among the 23 histologic cases show-
ing a homogeneous EGFR asset in the whole tumor, only 2
(9%) were discordant when compared with cytology.
DISCUSSION
Our finding indicates that EGFR FISH on cytology
specimens could be feasible, reliable, and equally informative
as FISH on histologic sample. In most patients with NSCLC,
small biopsies or cytologic sampling must provide sufficient
material for morphologic diagnosis and predictive marker
analyses. The benefit of EGFR TKIs is associated with
molecular alterations, including EGFR mutations and in-
creased copy number of the EGFR gene. Nevertheless, almost
all the previous studies on these biologic factors in lung
cancer were based on surgical specimens or biopsy material.
In this and previous experience,8 the feasibility of EGFR
FISH on cytologic samples has been demonstrated.
In this study, applying the criteria of Cappuzzo et al.,5
we have found a good concordance (87%) of EGFR FISH
patterns on cytologic samples from primary NSCLC and
those obtained on matched histologic sections. Three of the
four discordant cases were high polysomic on cytology and
low polysomic on histology (one case disomic and two cases
high trisomic). This discordance might be ascribed to the fact
that tissue sections from paraffin-embedded samples are ex-
pected to display a lower EGFR copy number than cytologic
specimens because of nuclear truncation. The fourth discor-
dant sample was scored high polysomic on histology and high
trisomic on cytology. In our opinion nuclear truncation is not
the only factor influencing the results; actually intratumoral
heterogeneity, that often occurs in NSCLC, may affect the
sampling both on cytologic smears and on small biopsies.
Lung cancers are often heterogeneous at both protein
and genetic levels with variable degree of EGFR protein
expression, gene amplification, and mutational status within
the same tumor lesion,9 and our study demonstrate that this
TABLE 1. EGFR FISH on 31 Cytological and Matched
Histological Specimens from Primary NSCLCs
Cytological
Specimens
(%) (n  31)
Histological
Specimens
(%) (n  31)
Concordant
Cases
(%) (n  27)
FISH positive 19 (61) 17 (55) 16 (52)
High polysomy 17 (55) 15 (49) 14 (46)
Amplification 2 (6) 2 (6) 2 (6)
FISH negative 12 (39) 14 (45) 11 (35)
Total concordance:
87% (27 of 31)
*K  0.736; p  0.001
EGFR  epidermal growth factor receptor; FISH  fluorescence in situ hybridi-
sation; *K  Kappa coefficient.
TABLE 2. EGFR FISH Cytology and FISH Histology

















EGFR FISH negative: disomy (1), low trisomy (2), high trisomy (3), and low
polysomy (4).
EGFR FISH positive: high polysomy (5) and gene amplification (6).
● indicates concordant cases and * indicates discordant cases.
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heterogeneity proved consistent in both cytology and histol-
ogy matched specimens.
In NSCLC, increased EGFR gene copy number most
frequently results from chromosome 7 polysomy, whereas true
EGFR amplification occurs less often.10 In agreement with the
current literature, we found 6% of EGFR cases amplified on
both cytology and histology.5–7 Only one previous study, pub-
lished by Savic et al.,11 reported a similar comparison about
EGFR gene analysis between cytologic and histologic samples
from primary NSCLC. In a series of 84 cytologic specimens
they demonstrated, in agreement with us, that EGFR gene
analysis is feasible in routinely processed cytologic samples.
Nevertheless, in a subgroup of 26 matched cytologic and histo-
logic specimens from primary NSCLC, they found a signifi-
cantly higher FISH-positive rate in cytologic specimens than in
matched biopsy (61.5% versus 27%), suggesting that specific
criteria for a EGFR FISH status in cytologic samples need to be
defined. The major difference between that work and our data
likely reflects the different sampling procedure used for cytol-
ogy. In that work, cytologic samples were mostly represented by
bronchial washings and brushings, known as exfoliative cytol-
ogy, rather than by multidirectional and targeted aspiration
cytology, which was the prevalent procedure in our series. It
cannot be excluded that EGFR FISH-positive status in bronchial
exfoliative samples of patients with NSCLC may indicate an
early EGFR gene abnormality in nontumor bronchial cells due
to field carcinogenic effects.12 Increased EGFR expression in
metaplastic tissue compared with normal mucosa has been
reported,13,14 demonstrating a statistically significant stepwise
increase in EGFR expression from normal bronchial mucosa to
epithelial hyperplasia to cancer suggesting a progressive EGFR
involvement in lung carcinogenesis.
In conclusion, within the limit of a small series, our data
indicate that FISH on NSCLC cytology may provide a reliable
and reproducible EGFR gene copy number definition when the
cytologic material is appropriately obtained from the tumor
mass. Giving the increasing importance of EGFR FISH assess-
ment in selecting patients for EGFR inhibitor treatment, our
study suggest the possible use of cytology as source to guide
individualized therapy, sparing more invasive biopsy procedure.
Our observation, nevertheless, should be verified in a more large
series and also related to EGFR TKI treatment outcome.
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FIGURE 1. Dual-color fluorescence in situ hy-
bridization assays using epidermal growth fac-
tor receptor (red)/CEP7 (green) probe (Vysis,
Downers Grove, IL) in cytologic specimens:
disomy (A), high polysomy (B), and gene am-
plification (C).
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